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Abstract. 
 
Leukocyte adhesion to vascular endothelium 
under flow involves an adhesion cascade consisting of 
multiple receptor pairs that may function in an overlap-
ping fashion. P-selectin glycoprotein ligand-1 (PSGL-1) 
and L-selectin have been implicated in neutrophil ad-
hesion to P- and E-selectin under flow conditions. To 
study, in isolation, the interaction of PSGL-1 with P- and 
E-selectin under flow, we developed an in vitro model 
in which various recombinant regions of extracellular 
 
PSGL-1 were coupled to 10-
 
m
 
m-diameter micro-
spheres. In a parallel plate chamber with well defined 
flow conditions, live time video microscopy analyses re-
vealed that microspheres coated with PSGL-1 attached 
and rolled on 4-h tumor necrosis factor-
 
a
 
–activated en-
dothelial cell monolayers, which express high levels of 
E-selectin, and CHO monolayers stably expressing 
E- or P-selectin. Further studies using CHO-E and -P 
monolayers demonstrate that the first 19 amino acids 
of PSGL-1 are sufficient for attachment and rolling on 
both E- and P-selectin and suggest that a sialyl Lewis 
x–containing glycan at Threonine-16 is critical for this 
sequence of amino acids to mediate attachment to 
E- and P-selectin. The data also demonstrate that a sul-
fated, anionic polypeptide segment within the amino 
terminus of PSGL-1 is necessary for PSGL-1–mediated 
attachment to P- but not to E-selectin. In addition, the 
results suggest that PSGL-1 has more than one binding 
site for E-selectin: one site located within the first 19 
amino acids of PSGL-1 and one or more sites located 
between amino acids 19 through 148.
 
A
 
 
 
critical step in the recruitment of leukocytes to a site
of inflammation is the adhesion of the leukocytes
to the vascular endothelium in the fluid dynamic
environment of the microcirculation. This adhesion pro-
cess involves a cascade of events including initial attach-
ment, rolling, spreading, and ultimately transendothelial
migration (11, 20, 28, 50). In vivo and in vitro studies have
shown that the inducible endothelial cell adhesion mole-
cules P-selectin (CD62P) and E-selectin (CD62E) are in-
volved in leukocyte initial attachment and rolling on acti-
vated vascular endothelium (1, 20–22, 29–31). The third
known member of the selectin family, L-selectin (CD62L),
is expressed only on leukocytes and is also involved in leu-
kocyte recruitment (4, 16, 22–24, 46, 50). The expression of
E-selectin requires de novo protein synthesis and can be
elicited by a 4-h treatment of cultured endothelium with
certain Gram-negative endotoxins and cytokines such as
IL-1 and tumor necrosis factor-
 
a
 
 (TNF-
 
a
 
)
 
1
 
 (7). P-selectin
is stored in the Weibel-Palade bodies of endothelial cells
and is rapidly mobilized to the cell surface by secreta-
gogues such as thrombin and histamine (32). The cytokine
activation pathway may also elicit limited P-selectin ex-
pression on cultured human umbilical vein endothelium
(29, 30). A notable feature of the selectins is their NH
 
2
 
-ter-
minal, lectin-like domain that binds carbohydrate moieties
in a Ca
 
2
 
1
 
-dependent manner (6). Thus, several carbohy-
drate ligands for P- and E-selectin have been proposed in-
cluding the sialyl Lewis x (SLe
 
x
 
) tetrasaccharide and re-
lated glycans (15, 41, 53).
Recent studies have focused on identifying the underly-
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1. 
 
Abbreviations used in this paper
 
: CHO-E, and -P, CHO cell monolayers
stably expressing E- or P-selectin; DPBS, Dulbecco’s phosphate buffered
saline; Fuc-TVII, 
 
a
 
(1,3)fucosyltransferase-VII; HUVEC, human umbili-
cal vein endothelial cell(s); OSGE, 
 
O
 
-sialoglycoprotein endopeptidase;
PSGL-1, P-selectin glycoprotein ligand-1; RT, room temperature; SLe
 
x
 
,
sialyl Lewis x; TNF-
 
a
 
, tumor necrosis factor-
 
a
 
.
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ing leukocyte proteins which present carbohydrate ligands
for binding to E- and P-selectin. Perhaps the best charac-
terized of these is P-selectin glycoprotein ligand-1 (PSGL-1),
which was first isolated from HL-60 cells (33) and subse-
quently cloned from an HL-60 cell cDNA library (43).
PSGL-1, a homodimer of disulfide-linked subunits with an
apparent molecular mass of 120 kD each (33), is present
on a variety of leukocytes including neutrophils, mono-
cytes, and lymphocytes (35). PSGL-1 is extensively glyco-
sylated with N-linked glycans and closely spaced O-linked
glycans, a portion of which are modified by SLe
 
x
 
 (34, 37,
54). L-selectin expressed on myeloid leukocytes also has
been proposed as a ligand for E- and P-selectin since, simi-
larly to PSGL-1, it displays SLe
 
x
 
-type structures and is lo-
calized on the tips of microvilli (22, 35, 39).
In vitro flow adhesion assays have investigated PSGL-1–
and L-selectin–mediated leukocyte adhesion to E- and
P-selectin under fluid flow. Patel et al. (38) measured neu-
trophil accumulation on CHO cell monolayers stably ex-
pressing P-selectin (CHO-P) or E-selectin (CHO-E). Based
on mAb blocking studies, the authors inferred that PSGL-1
is necessary for attachment of neutrophils to P-selectin
and for optimal attachment to E-selectin. In contrast, they
also reported that neutrophils pretreated (in the presence
of cytochalasin D to prevent shape change) with fMLP, a
chemoattractant known to induce endoproteolytic cleav-
age of L-selectin, did not accumulate on CHO-P or -E
monolayers but did retain functional PSGL-1–dependent
binding sites for P-selectin (38). A separate study (22) re-
ported that the accumulation of neutrophils on soluble
E-selectin under flow was inhibited (
 
z
 
90%) by mAbs to
L-selectin. The authors inferred that neutrophil attach-
ment to E-selectin under flow requires L-selectin, imply-
ing that PSGL-1 is not sufficient to mediate attachment to
E-selectin under flow. mAb approaches have suggested
the involvement of PSGL-1 in neutrophil rolling, subse-
quent to attachment, on E- and P-selectin (35, 38). How-
ever, since attachment is a prerequisite for rolling, if the
attachment step is blocked by an mAb to PSGL-1 (35, 38),
it is difficult to determine if PSGL-1 can mediate adhesive
events subsequent to attachment such as rolling. There-
fore, while it appears that PSGL-1 is involved in neutro-
phil attachment to E- and P-selectin, it is unclear if PSGL-1
is sufficient to mediate attachment and rolling.
Previous studies have investigated PSGL-1 regions nec-
essary for recognition of P- and E-selectin (42, 44). These
studies have revealed that an anionic polypeptide segment
containing three tyrosine residues, at least one of which is
sulfated, is located within the amino terminus of mature
PSGL-1 (42, 44). This region is necessary for fluid phase
PSGL-1 recognition of cell surface–expressed P-selectin
but is unnecessary for fluid phase PSGL-1 recognition of
cell surface–expressed E-selectin (44). However, the struc-
ture–function relationship for PSGL-1 and E- and P-selec-
tin has not been investigated in the more relevant (49) in
vitro flow assay.
To examine isolated PSGL-1 attachment and rolling on
E- and P-selectin, we have studied the adhesion of 10-
 
m
 
m-
diam nondeformable microspheres, coated with various
extracellular regions of PSGL-1, to TNF-
 
a
 
–activated cul-
tured human endothelium and to CHO-E and -P monolay-
ers under defined flow conditions. The results demonstrate
 
that: (
 
a
 
) PSGL-1 is sufficient to mediate microsphere at-
tachment and rolling on TNF-
 
a
 
–activated endothelial
monolayers and on CHO-E and -P monolayers; (
 
b
 
) the first
19 amino acids of PSGL-1 are sufficient for attachment
and rolling on both E- and P-selectin; (
 
c
 
) an SLe
 
x
 
 contain-
ing O-glycan at Threonine-16 is critical for the first 19
amino acids of PSGL-1 to mediate attachment to E- and
P-selectin; (
 
d
 
) the anionic polypeptide segment within the
amino terminus of PSGL-1 is necessary for PSGL-1–medi-
ated attachment to P- but not E-selectin; and (
 
e
 
) PSGL-1
has more than one binding site for E-selectin: one site lo-
cated within the first 19 amino acids of PSGL-1 and one or
more sites located between amino acids 19 through 148.
 
Materials and Methods
 
Materials
 
RPMI-1640 containing 1 mM 
 
l
 
-glutamine and 20 mM Hepes, Alpha me-
dia, DPBS with (DPBS
 
1
 
) or without Ca
 
2
 
1
 
 and Mg
 
2
 
1
 
, were obtained from
Biowhittaker (Walkersville, MD). FBS and dialyzed FBS were obtained from
Hyclone Labs (Urem, UT). 
 
O
 
-sialoglycoprotein endopeptidase (OSGE)
was obtained from Accurate Chemicals (Westbury, NY). Neuraminidase
from 
 
Vibrio cholerae
 
 was obtained from Boehringer Mannheim Corp. (In-
dianapolis, IN). BSA was obtained from Sigma Chemical Co. (St. Louis,
MO). All other chemicals were of the highest grade available from J.T.
Baker, Inc. (Phillipsburg, NJ).
 
Antibodies
 
Function blocking murine mAb to E-selectin 7A9 (IgG
 
1
 
) was obtained
from American Type Culture Collection (Rockville, MD) (clone HB 10135)
and used as F(ab
 
9
 
)
 
2
 
 (10 
 
m
 
g/ml). Nonblocking murine mAb to E-selectin
H4/18 (IgG
 
1
 
) was used as F(ab
 
9
 
)
 
2
 
 (10 
 
m
 
g/ml). Leukocyte function blocking
murine anti–P-selectin mAb, HPDG2/3 (IgG
 
1
 
) (43), was used as F(ab
 
9
 
)
 
2
 
(10 
 
m
 
g/ml), and nonblocking murine anti–P-selectin mAb, HPDG2/1 (IgG
 
1
 
)
(43), was used as purified IgG
 
1
 
 (10 
 
m
 
g/ml). The following antibodies rec-
ognize human PSGL-1 and have been described previously: murine mAb
PSL-275 (IgG
 
1
 
; purified IgG, 20 
 
m
 
g/ml) (43, 48) and polyclonal rabbit sera,
Rb3026 (1:20 dilution) (43, 48). Normal rabbit sera (1:20 dilution) was
used as a control for Rb3026. mAbs KPL1 and KPL2 (Snapp, K.R., F.W.
Luscinskas, R. Warnke, and G.S. Kansas. 1997. 
 
J. Allergy Clin. Immunol.
 
99:s459) recognize PSGL-1 and were used as ascites (1:200 dilution for ad-
hesion assays and 1:500 for flow cytometric analysis) and purified IgG.
Murine antihuman IgG
 
1
 
 Fc specific (CALTAG Laboratories, San Fran-
cisco, CA) was used as a control for the purified KPL1. Murine anti–
ICAM-1 mAb Hu5/3 (IgG
 
1
 
) was used as purified IgG (20 
 
m
 
g/ml). Murine
antibody to human Class I, W6/32, (IgG
 
2a
 
) was used as F(ab
 
9
 
)
 
2
 
 (10 
 
m
 
g/ml).
FITC-labeled goat F(ab
 
9
 
)
 
2
 
 secondary antibodies (each at 1:50 dilution) to
rabbit IgG, mouse IgG, and human Fc were obtained from CALTAG
Laboratories. FITC-labeled goat F(ab
 
9
 
)
 
2
 
 secondary antibody (1:50 dilu-
tion) to mouse Fc and unlabeled goat F(ab
 
9
 
)
 
2
 
 were obtained from Jackson
ImmunoResearch Laboratories (West Grove, PA).
 
Cell Culture
 
CHO cells stably expressing human E-selectin (CHO-E) or human P-selectin
(CHO-P) were prepared and cultured in Alpha media containing 10% dia-
lyzed FBS as previously detailed (43). Human umbilical vein endothelial
cells (HUVEC) were isolated and cultured as described previously (28).
For induction of adhesion molecule expression, HUVEC monolayers
were activated by a 4-h treatment with 25 ng/ml TNF-
 
a
 
 (29).
 
Soluble Forms of PSGL-1
 
The PSGL-1 molecules used in these studies are chimeras consisting of
various truncated extracellular regions of mature PSGL-1 fused to the
heavy chain CH2-CH3 (Fc) region of human IgG
 
1
 
. Their construction, ex-
pression, and selectin-binding properties have been described previously
(44). In the present studies, plasmids encoding two of these chimeras, 
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148.Fc and 
 
D
 
Y148.Fc (abbreviated to 
 
D
 
Y.Fc here), were transfected into
COS cells as described except for the substitution of a plasmid encoding
an 
 
a
 
(1,3)fucosyltransferase-VII (Fuc-TVII) enzyme (36, 45) for the Fuc-
TIII plasmid used in earlier cotransfections (44). The resulting condi-
tioned media were supplemented with 0.002% NaN
 
3
 
 and 10 
 
m
 
M PMSF and
then clarified by centrifugation. Fc chimeras were purified by protein
A–Sepharose (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ) chro-
matography per the manufacturer’s instructions and quantified by an anti-Fc
enzyme-linked immunosorbent assay using human IgG
 
1
 
 (Sigma Chemical
Co.) as a standard. The 19.Fc form of PSGL-1 described earlier (44) was
mutated to include an enterokinase cleavage site (19) located between the
PSGL-1 and IgG Fc regions and is termed 19.ek.Fc. A plasmid encoding
this construct was stably transfected into CHO cells that were engineered
to also express Fuc-TVII and 
 
b
 
(1,6)-
 
N
 
-acetylglucosaminyltransferase
(“core2” [9]) activities (17, 25). 19.ek.Fc was purified from conditioned
media and quantified as above. Similar to COS produced 19.Fc, 19.ek.Fc
is tyrosine sulfated and glycosylated with SLe
 
x
 
-type containing 
 
O
 
-glycans
and, in E- and P-selectin binding experiments (44), is functionally indistin-
guishable (data not shown). The nomenclature for microspheres coated
with various extracellular regions of PSGL-1 is as follows: the 148.Fc con-
struct, 148.Fc microspheres; the 19.ek.Fc construct, 19.ek.Fc microspheres;
the 
 
D
 
Y.Fc construct, 
 
D
 
Y.Fc microspheres (see Fig. 6 
 
a
 
).
 
Preparation, Flow Cytometric Analysis, and Enzymatic 
Treatment of PSGL-1 Microspheres
 
Preparation.  
 
10-
 
m
 
m nondeformable polystyrene microspheres (Poly-
sciences Inc., Warrington, PA) were washed twice in 0.1 M NaHCO
 
3
 
, pH
9.2, and incubated (2.5 
 
3
 
 10
 
7
 
 microspheres/ml) overnight at room temper-
ature (RT) with 300 
 
m
 
g/ml protein A (Zymed Labs, South San Francisco,
CA) in 0.1 M NaHCO
 
3
 
, pH 9.2, with end-to-end rotation. Microspheres
were washed twice with DPBS and blocked for 30 min at RT with DPBS
containing 1% BSA. After the blocking step, the microspheres (2 
 
3
 
 10
 
8
 
microspheres/ml) were incubated with a PSGL-1.Fc extracellular con-
struct or human IgG
 
1
 
 diluted in DPBS for 1 h at RT with agitation. The
microspheres were washed with DPBS
 
1
 
, 1% BSA and blocked with
DPBS
 
1
 
, 1% BSA containing 200 
 
m
 
g/ml human IgG
 
1
 
 kappa or lambda
(Sigma Chemical Co.). Microspheres were held in this buffer at 1 
 
3
 
 10
 
8
 
microspheres/ml at RT for 1 h before use in the assays.
 
Indirect Immunofluorescence and Flow Cytometric Analysis of PSGL-1
Microspheres.  
 
After the human IgG
 
1
 
 blocking step, replicate aliquots (
 
z
 
5
 
3
 
 10
 
5
 
) of microspheres were washed in DPBS
 
1
 
 containing 1% BSA and
incubated for 20 min at RT with 20 
 
m
 
g/ml primary mAb in DPBS
 
1
 
, 1%
BSA. After incubation, microspheres were washed and blocked with unla-
beled goat F(ab
 
9
 
)
 
2
 
 fragments (100 
 
m
 
g/ml), and the primary mAb was de-
tected with FITC-labeled F(ab
 
9
 
)
 
2
 
 fragments of goat anti–mouse Fc-spe-
cific secondary antibody. The microspheres were incubated for 20 min at
RT, washed twice in DPBS
 
1
 
, 1% BSA, once in DPBS
 
1
 
, and fixed with
2% formaldehyde in DPBS
 
1
 
. FITC fluorescence was determined on a
FACScan
 
®
 
 flow cytometer (Becton-Dickinson Immunocytometry Sys.,
Mountain View, CA) by counting the fluorescence of 5,000 or 10,000 mi-
crospheres. The data are presented as single parameter histograms on a
four-decade scale.
 
OSGE Treatment of PSGL-1 Microspheres.  
 
Microspheres were prepared
as described above up to blocking with human IgG
 
1
 
. A suspension of
PSGL-1–coated microspheres (1 
 
3
 
 10
 
8
 
/ml) was incubated in DPBS
 
1
 
,
0.2% FBS, 0.05% NaN
 
3
 
, 25 mM Hepes, pH 7.4, with or without 160 
 
m
 
g/ml
OSGE for 30 min at 37
 
8
 
C. The microspheres were then washed with
DPBS
 
1
 
, 1% BSA and blocked with DPBS
 
1
 
, 1% BSA containing 200 
 
m
 
g/ml
human IgG1 at 1 3 108 microspheres/ml. The microspheres used in the
flow cytometric analysis to detect human Fc were incubated with 0.2% nor-
mal rabbit serum instead of human IgG1, blocked with 100 mg/ml unla-
beled goat (Fab9)2 fragments, and then stained with goat FITC-labeled
(Fab9)2 fragments of antibodies to either human Fc or mouse IgG.
Sialidase Treatment of PSGL-1 Microspheres.  Microspheres were pre-
pared with the 19.ek.Fc construct as described above. 19.ek.Fc micro-
spheres were then washed twice in RPMI-1640, resuspended to 1 3 108 in
RPMI-1640 with or without 0.1 U/ml neuraminidase, and incubated for 30
min at 378C. Microspheres were then washed twice in DPBS1, 1% BSA
and blocked (1 3 108 microspheres/ml) with DPBS1, 1% BSA containing
200 mg/ml human IgG1.
Parallel Plate Flow Chamber Analysis
The parallel plate flow chamber apparatus used in these studies has been
described in detail (28). Temperature was maintained at 378C by a heating
plate. The flow apparatus was mounted on an inverted microscope (model
Diaphot; Nikon Inc., Melville, NY), and the entire perfusion period was
recorded on videotape by a video camera and VCR. Microspheres were
drawn through the chamber at 5 3 105 microspheres/ml in DPBS1, 0.5%
BSA, and microsphere attachment rates were quantified by observing a
103 field of view for z1 min and 15 s. The number of microspheres that
attached throughout this time period was determined and divided by the
time of observation and the area of the field of view to yield the rate of at-
tachment per unit area. For a given coverslip, an attachment rate was de-
termined at two different fields of view and the two values were averaged
to give an n 5 1. Microsphere accumulation was determined by counting
the number of microspheres interacting with the substrate in a particular
field of view (103 magnification). This value was determined for three to
five different fields of view between 3.5 to 4 min after initiation of micro-
sphere perfusion. These numbers were averaged and normalized to the
area of the field of view. Rolling velocities were determined manually by
measuring the distance a microsphere traveled in a given amount of time.
Antibody Blocking Experiments
All control or blocking antibodies to molecules on the cell monolayers
were diluted (10 mg/ml) in the appropriate media and added to the mono-
layers 20 min before the adhesion assays described above. For mAb block-
ing of the PSGL-1 microspheres, 10–15 ml of a 1 3 108 microsphere/ml
suspension was mixed 1:1 with DPBS1, 1% BSA containing a 1:100 dilu-
tion of ascites mAb KPL1 or KPL2. This suspension was allowed to incu-
bate for 15 min at RT, diluted to 5 3 105 microspheres/ml in DPBS1,
0.5% BSA, and used immediately in the flow chamber assay.
Statistics
All differences were evaluated by a two-tailed Student’s t test. P values
represent the results of these t tests and values <0.05 were considered sig-
nificant. All error bars represent standard deviations.
Results
A PSGL-1.Fc Chimera Can Be Coupled to Polystyrene 
Microspheres Precoated with Protein A
Previous investigators have developed methods to couple
biotinylated SLex (10) or various mAbs (18, 40) to micro-
spheres and used the resulting microspheres as model cells
in adhesion assays. We adapted these techniques to study
the interaction of PSGL-1, in isolation, with E- and P-selectin
under fluid flow. Sako et al. (44) have generated and de-
scribed recombinant PSGL-1.Fc constructs that consist of
various portions of the extracellular region of PSGL-1
fused to the Fc region of human IgG1. The presence of the
Fc region led to the idea of coupling the PSGL-1.Fc con-
structs to microspheres precoated with protein A. Such an
approach allows for the “correct” orientation of PSGL-1.Fc
chimera on the microsphere, i.e., the PSGL-1 portion of the
PSGL-1.Fc chimera oriented away from the microsphere
and available for binding to other molecules and the Fc
portion of the chimera coupled to the protein A adsorbed
to the surface of the microsphere. Although recombinant
forms of PSGL-1 may differ slightly from native PSGL-1,
other investigators have used recombinant forms of PSGL-1
to gain significant insights into the biochemistry of PSGL-
1–E- and –P-selectin interactions (25, 42, 44) . In addition,
Sako et al. (44) have documented that recombinant and
native PSGL-1 exhibit similar function in a variety of bio-
chemical assays.
In initial studies, 148.Fc, a truncated PSGL-1 construct
consisting of the first 148 amino acids of PSGL-1 linked to
the Fc region of human IgG1 (44), was coupled to 10-mm-The Journal of Cell Biology, Volume 137, 1997 512
diam polystyrene microspheres precoated with protein A
to generate 148.Fc microspheres. The 148.Fc version of
PSGL-1 was used, as it was demonstrated previously to ex-
hibit high affinity binding to both E- and P-selectin under
static conditions when produced in the presence of an
SLex-generating fucosyltransferase (44). We chose to use
10-mm-diam microspheres since such microspheres have a
density (1.05 g/ml) and diameter similar to that of leuko-
cytes. The presence of the 148.Fc chimera on the surface
of the 148.Fc microsphere was detected with an mAb to
PSGL-1, PSL-275 (Fig. 1, a–e). The amount of 148.Fc chi-
mera bound to the microspheres was concentration depen-
dent (Fig. 1, a–e). An isotype-matched control mAb, Hu5/3,
did not recognize microspheres coated with 100 mg/ml
148.Fc, the highest coating concentration used (Fig. 1 f).
From this data we conclude that the 148.Fc chimera was
bound to the protein A–coated microspheres. Preliminary
studies indicated that microspheres prepared with 50 mg/ml
of the 148.Fc construct gave consistent results in the flow
adhesion assays. Hence, a coating concentration of 50 mg/ml
was used in the remainder of the studies unless otherwise
noted.
148.Fc Microspheres Attach and Roll on
TNF-a–stimulated HUVEC
Previous studies have revealed that 4-h TNF-a–stimulated
cultured HUVEC express high levels of E-selectin (7) and
that E-selectin is involved in neutrophil accumulation on
cytokine-activated HUVEC under in vitro flow conditions
(1). While PSGL-1 has been implicated in neutrophil accu-
mulation on CHO-E monolayers (38), it is unclear if
PSGL-1 is sufficient to mediate attachment and rolling on
E-selectin (22, 38). In addition, there is very little data on
PSGL-1 interactions with TNF-a–stimulated cultured en-
dothelium. Hence, we sought to determine if PSGL-1 is
sufficient to mediate attachment and rolling on TNF-a–
stimulated HUVEC.
At 2 dynes/cm2, 148.Fc microspheres attached to 4-h
TNF-a–activated HUVEC at a rate of 101 6 14 micro-
spheres/mm2/min (Fig. 2). The attachment events were in-
hibited by F(ab9)2 fragments of a blocking anti–E-selectin
mAb, 7A9, but unaffected by F(ab9)2 fragments of an en-
dothelial cell binding control mAb anti–Class I, W6/32,
indicating that the attachment was mediated by E-selectin
(Fig. 2). Unstimulated HUVEC, which do not express
E-selectin (7), did not support attachment of 148.Fc micro-
spheres (Fig. 2). Microspheres coated with human IgG1
did not attach to TNF-a–stimulated HUVEC (Fig. 2). Sub-
sequent to attachment, .95% of the attached 148.Fc mi-
crospheres rolled in a manner similar to that described for
leukocytes (Fig. 3), i.e., a low-velocity, high-variance trans-
lation (12). Thus, it appears that the first 148 amino acids
of PSGL-1 are sufficient to support initial attachment and
Figure 1. A PSGL-1.Fc chimera molecule can be coupled to pro-
tein A microspheres. 10-mm microspheres were precoated with
protein A. These microspheres were then incubated with various
concentrations of the 148.Fc chimera. The amount of 148.Fc chi-
mera bound to the microspheres was detected with an mAb to
PSGL-1 (a–e), PSL-275, and an appropriate FITC-labeled sec-
ondary antibody. Isotype-matched control mAb to ICAM-1,
Hu5/3, did not recognize the 148.Fc chimera (f ).
Figure 2. 148.Fc microspheres attached and rolled on TNF-a–acti-
vated HUVEC monolayers under flow. 148.Fc or IgG micro-
spheres were perfused across TNF-a– (4 h, 25 ng/ml) activated or
–unactivated HUVEC monolayers. 148.Fc microspheres attached
and rolled on TNF-a–activated HUVEC monolayers while IgG
microspheres did not attach to the TNF-a–activated HUVEC
monolayers. 148.Fc microsphere attachment was blocked by an
mAb to E-selectin (7A9) but unaffected by a negative isotype-
matched control endothelial cell binding mAb to Class I (W6/32).
148.Fc microspheres did not attach to unactivated HUVEC
monolayers. (Shear stress 5 2 dynes/cm2; n 5 3).Goetz et al. PSGL-1-mediated Attachment of Microspheres 513
subsequent rolling on TNF-a–activated endothelium and
that the attachment step is mediated by E-selectin.
148.Fc Microspheres Attach and Roll on CHO-P
and -E Monolayers
While it appears that PSGL-1 is necessary for accumula-
tion of neutrophils on CHO-P monolayers, it is unclear if
PSGL-1 is sufficient to mediate attachment and rolling
(38). To determine if PSGL-1 is sufficient to mediate at-
tachment and rolling on P-selectin and to further test the
hypothesis that PSGL-1 is sufficient to mediate attach-
ment and rolling on E-selectin, we studied the interaction
of 148.Fc microspheres with CHO-P and -E monolayers.
At 2 dynes/cm2, 148.Fc microspheres attached to CHO-E
and -P monolayers at a rate of 122 6 50 microspheres/
mm2/min and 119 6 43 microspheres/mm2/min, respec-
tively (Fig. 4). Subsequent to attachment, .95% of the at-
tached 148.Fc microspheres rolled on either CHO-E or -P
monolayers. Function blocking F(ab9)2 mAbs to E- (7A9)
and P-selectin (HPDG2/3) completely inhibited the attach-
ment of 148.Fc microspheres to CHO-E and -P monolayers,
respectively (Fig. 4). In contrast, control isotype-matched
F(ab9)2 preparation of mAb W6/32 and non–function block-
ing mAbs to E- (H4/18) and P-selectin (HPDG2/1) (Fig. 4
and data not shown) had no effect on the rate of attach-
ment of the 148.Fc microspheres to CHO-E and -P mono-
layers, respectively. Under identical conditions, the 148.Fc
microspheres did not attach to the parental CHO cell line
(n 5 2, data not shown), nor did human IgG1 microspheres
attach to CHO-P or -E monolayers (Fig. 4). Thus, it ap-
pears that the first 148 amino acids of PSGL-1 are suffi-
cient to support attachment and subsequent rolling on
CHO cell monolayers expressing E- or P-selectin.
Attachment of 148.Fc Microspheres to CHO-E
and -P Cell Monolayers Is Eliminated by Pretreatment 
of 148.Fc Microspheres with OSGE
Previous studies have demonstrated that PSGL-1 is cleaved
by the metalloprotease OSGE (37). To investigate the speci-
ficity of the 148.Fc microsphere attachment events, we
treated 148.Fc microspheres with OSGE before use in our
flow assay. Treatment of the 148.Fc microspheres with
OSGE significantly reduced (.95%) the presence of the
epitope recognized by the PSGL-1 mAb PSL-275 (Fig. 5 A).
However, the level of human IgG Fc present on the micro-
sphere was unchanged indicating that the PSGL-1 peptide
of the 148.Fc chimera was specifically cleaved by OSGE
(Fig. 5 A). Treatment of 148.Fc microspheres with OSGE
before use in the flow assay eliminated attachment to both
CHO-P and -E monolayers (Fig. 5 B). From these data, we
conclude that 148.Fc microsphere attachment to CHO-E
Figure 3. 148.Fc microspheres rolled on TNF-a–stimulated
HUVEC. The image shows two 148.Fc microspheres (white
spheres) rolling over a TNF-a–activated HUVEC monolayer
(gray background). Images were captured, every 0.6 s, from a vid-
eotape of the experiment and layered together to give the com-
posite image shown. Note that the 148.Fc microspheres translated
in the direction of the flow with a nonconstant velocity. The aver-
age velocity of 10 different 148.Fc microspheres was determined
and found to be 14 mm/sec, which is ,3% of the hydrodynamic
velocity of a noninteracting hard sphere translating 50 nm from
the surface (13). The length of the image shown is 100 mm. Shear
stress 5 2 dynes/cm2.
Figure 4. 148.Fc microspheres
attached and rolled on CHO-P
and -E monolayers. 148.Fc mi-
crospheres attached and rolled
on CHO-E and -P monolayers
while IgG microspheres did not
attach to either CHO mono-
layer. 148.Fc microsphere at-
tachment to CHO-E and -P
monolayers was blocked by an
mAb to E-selectin (7A9) and an
mAb to P-selectin (HPDG2/3),
respectively, but was unaffected
by an isotype-matched control
mAb (W6/32). 148.Fc micro-
spheres did not attach to the pa-
rental CHO cell line (data not
shown). (Shear stress 5 2 dynes/
cm2; n 5 3).The Journal of Cell Biology, Volume 137, 1997 514
and -P monolayers is specifically mediated by the PSGL-1
peptide of the 148.Fc chimera.
PSGL-1 Regions Necessary and/or
Sufficient for Attachment and Rolling on CHO-E
and -P Monolayers
By using Fc constructs consisting of various extracellular
portions of PSGL-1, Sako et al. (44) identified an NH2-ter-
minal anionic polypeptide region within PSGL-1 neces-
sary for recognition of P- but not E-selectin under static
conditions. This sequence is rich in acidic amino acids and
contains one or more tyrosine sulfate residues (42, 44). To
determine whether this region of PSGL-1 is necessary and/or
sufficient for attachment and rolling on P- and E-selectin,
we used two additional Fc constructs cited in the earlier study
(44) (Fig. 6 a). One of these constructs, DY.Fc (44), is a
mutated form of the 148.Fc chimera with an internal dele-
tion within the anionic polypeptide region, specifically
amino acids 5–11. The second construct, 19.ek.Fc, is a
modified version of the 19.Fc construct used in the earlier
study (44). 19.ek.Fc contains only the first 19 amino acids
of PSGL-1, which includes the anionic, sulfated tyrosine
region and a critical O-linked glycosylation site at Threo-
nine-16, Thr-16, also present in the 148.Fc. Unique to the
19.ek.Fc construct is a cleavable polypeptide sequence in-
troduced between the PSGL-1 and Fc sequences. This ad-
ditional sequence contains no potential sites for glycosyla-
tion. The DY.Fc construct has a similar molecular weight
as the 148.Fc (44) and, because of material limitations, was
coupled to microspheres at a concentration of 40 mg/ml.
For these experiments, 148.Fc microspheres were also pre-
pared at this concentration. Since the molecular weight of
the 19.ek.Fc is a little over 1/3 that of the 148.Fc, we pre-
pared the 19.ek.Fc microspheres with 15 mg/ml of the
19.ek.Fc. As shown with a polyclonal antibody to PSGL-1,
Rb3026, both mutants were coupled to the microspheres
(Table I).
19.ek.Fc microspheres attached to CHO-E and -P mono-
layers at a rate similar to that observed for 148.Fc micro-
spheres (Fig. 6 b). Subsequent to attachment, .95% of the
19.ek.Fc microspheres were observed to roll on both the
CHO-E and -P monolayers. DY.Fc microspheres attached
to CHO-E monolayers at a rate similar to that observed
for 148.Fc microspheres (Fig. 6 b). Subsequent to attach-
ment, .95% of the DY.Fc microspheres were observed to
roll. In contrast, DY.Fc microspheres did not attach to
CHO-P monolayers (Fig. 6 b). Neither the 19.ek.Fc nor
the DY.Fc microspheres attached to the parental CHO cell
line (n 5 2; data not shown). We next attempted to block
148.Fc and 19.ek.Fc microsphere attachment to CHO-E
and -P monolayers with an mAb, KPL1, specific for PSGL-1.
KPL1 blocks neutrophil and memory T cell adhesion to
Figure 5. OSGE abolishes 148.Fc microsphere attachment to CHO-P or -E monolayers. (A) 148.Fc microspheres were incubated with
buffer (a and c) or OSGE (b and d) at 378C for 30 min. Untreated (a) or OSGE-treated (b) 148.Fc microspheres were incubated with an
mAb to PSGL-1 (PSL-275) (open histograms) or an isotype-matched control mAb to ICAM-1 (Hu5/3) (shaded histograms) and subse-
quently an FITC-labeled secondary antibody. As a control for the specificity of OSGE, the presence of the human Fc region of the
148.Fc chimera was detected on the 148.Fc microspheres. Untreated (c) or OSGE-treated (d) 148.Fc microspheres were incubated with
an FITC-labeled polyclonal antibody to human Fc (open histograms) or control, mouse IgG (shaded histograms). Results shown are rep-
resentative of n 5 2–4 separate experiments. (B) Treatment of 148.Fc microspheres with OSGE before use in the in vitro flow assay
abolished 148.Fc microsphere attachment to CHO-E and -P monolayers. (Shear stress 5 2 dynes/cm2; P , 0.05; n 5 3).
Table I. Flow Cytometric Analyses of PSGL-1.Fc Constructs 
on Microspheres
Mean channel fluorescence
mAb IgG1 148.Fc DY.Fc 19.ek.Fc
NRS* 243 60 83 167
Rb3026 137 554 520 335
Hu5/3* 16 12 27 42
KPL1 12 1,595 11 461
KPL2 14 7 12 22
Microspheres were coated with indicated PSGL-1 molecules or human IgG and de-
tected with various mAbs as detailed in Methods. Results typical of 2–4 separate ex-
periments.
*Negative controls. NRS, normal rabbit serum.Goetz et al. PSGL-1-mediated Attachment of Microspheres 515
Figure 6. The first 19 amino acids of PSGL-1 are
sufficient for attachment to CHO-E and -P
monolayers, and the NH2-terminal anionic
polypeptide segment of PSGL-1 is necessary for
148.Fc-mediated attachment to CHO-P, but not
CHO-E monolayers. (a) Schematic representa-
tion of the PSGL-1.Fc constructs. Closed bars,
PSGL-1 segments; open bars, human Fc seg-
ments;  open bar with X, an internal deletion of
amino acids 5–11 within the NH2-terminal an-
ionic polypeptide region; shaded bar, the enteroki-
nase cleavage site; Y, amino-terminal tyrosine;
vertical lines with open circles, the approximate
number and location of potential O-linked gly-
cosylation sites; vertical lines with closed circles, O-linked site at amino terminal threonine 16; vertical lines with shaded rectangles, po-
tential N-linked glycosylation sites. (Drawing not to scale.) (b) Microspheres coated with the 19.ek.Fc mutant (open bars), containing
the first 19 amino acids of PSGL-1, attached to CHO-P and -E monolayers at a rate similar to 148.Fc microspheres (dark bars). Micro-
spheres coated with the DY.Fc mutant, which consists of the first 148 amino acids of PSGL-1 with an internal deletion of the residues in
positions 5–11, attached to CHO-E monolayers at a rate similar to 148.Fc microspheres but did not attach to CHO-P monolayers (cross-
hatched bars). (Shear stress 5 2 dynes/cm2; n 5 2). (c) An mAb to PSGL-1, KPL1, which requires amino acids 5–11 to recognize PSGL-1
(Table I), did not affect attachment of 148.Fc microspheres to CHO-E monolayers but eliminated attachment to CHO-P monolayers.
148.Fc microspheres treated with mAb KPL1 attached to CHO-E monolayers at a rate similar to that observed for 148.Fc microspheres
treated with control mAb KPL2 but did not attach to CHO-P monolayers. (Shear stress 5 2 dynes/cm2; *P , 0.05; n 5 2). (d) mAb
KPL1 eliminated attachment of 19.ek.Fc microspheres to both CHO-E and -P monolayers. (Shear stress 5 2 dynes/cm2; *P , 0.05; n 5 2).
CHO-P monolayers (Snapp, K.R., F.W. Luscinskas, R.
Warnke, and G.S. Kansas. 1997. J. Allergy Clin. Immunol.
99:s459). As shown in the present study, KPL1 recognition
of the 148.Fc microspheres appears to be dependent on
the presence of amino acid sequence 5–11 of PSGL-1 (Ta-
ble I; 148.Fc versus DY.Fc). KPL2, a nonblocking isotype-
matched mAb specific to full-length PSGL-1 (Snapp, K.R.,
F.W. Luscinskas, R. Warnke, and G.S. Kansas. 1997. J. Al-
lergy Clin. Immunol. 99:s459) was used as a control. KPL2
appears to map to a PSGL-1 sequence COOH-terminal to
amino acid 148 as it does not react with any of the Fc con-
structs by flow cytometric analysis (Table I). For the block-
ing studies, we used ascites preparations of both KPL1 and
KPL2. KPL1 did not block 148.Fc microsphere attachment
to CHO-E monolayers but completely blocked attachment
to CHO-P monolayers (Fig. 6 c). 148.Fc microsphere at-
tachment to CHO-E monolayers was not inhibited by treat-
ment with a higher concentration of an ascites preparation
of KPL1 (1:100 vs. 1:200 dilution) or 80 mg/ml purified KPL1
relative to 148.Fc microspheres treated with control anti-
bodies (data not shown). In contrast, KPL1 blocked 19.ek.Fc
microsphere attachment to both CHO-E and -P monolay-
ers (Fig. 6 d). Similar inhibitory effects were obtained with
a purified IgG preparation of KPL1. Taken together, these
results show that: (a) The first 19 amino acids of PSGL-1
are sufficient to support attachment and rolling on both
CHO-P and -E monolayers; (b) the anionic polypeptide
segment within the amino terminus of PSGL-1 is neces-
sary for the 148.Fc construct to mediate attachment to
CHO-P, but not to CHO-E monolayers; and (c) the 148.Fc
construct contains at least two binding sites for E-selectin,
one located within the first 19 amino acids and a second
(or more) site COOH-terminal to amino acid 19.
An SLex-containing Glycan Is Involved in
19.ek.Fc Microsphere Attachment and Rolling on 
CHO-P and -E Monolayers
Previous studies have shown that treatment of neutrophils
(1), or HL-60 cells (2), with 0.1 U/ml neuraminidase for 30
min inhibits adhesion to P- and E-selectin under flow, sug-
gesting that sialylated structures, presumably SLex and/orThe Journal of Cell Biology, Volume 137, 1997 516
related glycans, are involved. However, since both neu-
trophils and HL-60 cells express multiple surface glycopro-
teins and glycolipids that may contain SLex-modified glycans,
it is difficult to ascribe the role of PSGL-1 glycosylation in
attachment and rolling on P- and E-selectin. We attempted
to address this issue in studies using 19.ek.Fc-coated mi-
crospheres in light of the data presented in the previous
section demonstrating that this highly defined construct is
sufficient for attachment and rolling on E- and P-selectin.
The PSGL-1 peptide region of the 19.ek.Fc construct con-
tains two potential O-linked glycosylation sites, Thr-3 and
Thr-16, but no N-linked glycosylation sites. Mass and NMR
spectroscopy of the enterokinase-liberated PSGL-1 pep-
tide from 19.ek.Fc indicated that of the two threonines,
only Thr-16 is glycosylated, and this glycan contains SLex
(data not shown). Preliminary studies with microspheres
coated with 15 mg/ml of the 19.ek.Fc construct indicated
that a sialylated glycan, presumably SLex, is critically in-
volved in the attachment of 19.ek.Fc microspheres to
CHO-E and -P monolayers since pretreatment of 19.ek.Fc
microspheres with 0.1 U/ml neuraminidase at 378C for 30
min diminished the rate of attachment to CHO-E mono-
layers by .95% and to CHO-P monolayers by .85% (data
not shown).
To further investigate the role of glycosylation, we pre-
pared 19.ek.Fc microspheres with 50 mg/ml 19.ek.Fc rather
than 15 mg/ml and used the same neuraminidase treatment
protocol. Treatment of 50 mg/ml 19.ek.Fc microspheres
with neuraminidase significantly diminished, if not elimi-
nated, attachment of 19.ek.Fc microspheres to CHO-E
monolayers (Fig. 7 a). In contrast, 19.ek.Fc microspheres
treated with neuraminidase attached to CHO-P monolay-
ers at a rate similar to untreated 19.ek.Fc microspheres
(Fig. 7 b). This result suggested that neuraminidase diges-
tion of the 50 mg/ml 19.ek.Fc microspheres was incom-
plete, but this treatment was sufficient to abolish attach-
ment to CHO-E but not CHO-P monolayers. Hence, a
higher level of sialylation, presumably the SLex at Thr-16,
is required for the 19.ek.Fc microspheres to attach to
CHO-E relative to CHO-P monolayers.
Comparison of the interactions of neuraminidase-treated
and -untreated 19.ek.Fc microspheres with CHO-P mono-
layers also revealed that neuraminidase treatment led to a
marked difference in the behavior of the 19.ek.Fc micro-
spheres subsequent to attachment. Typically, neuramini-
dase-treated 19.ek.Fc microspheres were observed to at-
tach to the CHO-P monolayers, roll and skip for several
microsphere diameters, and then detach. The net effect of
the increased rate of detachment was a decrease in the
accumulation relative to untreated 19.ek.Fc microspheres
(Fig. 7 c). The rolling velocities on CHO-P monolayers in-
creased fivefold from 2 mm/sec for untreated 19.ek.Fc mi-
crospheres to 10 mm/sec for neuraminidase-treated 19.ek.Fc
microspheres (P , 0.05; n 5 10 for each condition).
Discussion
The leukocyte–endothelial adhesion cascade is mediated
by an overlapping sequence of multiple receptor interac-
tions. Previous studies have used subtractive approaches,
such as antibody blocking, enzyme treatment, or activa-
tion-induced shedding, to determine if a given receptor is
involved in a particular adhesion process. While these ap-
proaches can determine if a receptor is necessary for an
adhesion event, such approaches are less likely to deter-
mine if a receptor is sufficient. Because of the requirement
of the presence of fucosyltransferases for generation of
functional PSGL-1 (25, 43), the additive transfection ap-
proach has the caveat of potential alteration of other cell
surface molecules to the extent that they may be able to
interact with E- (27, 52) or perhaps P-selectin. Hence, to
determine if PSGL-1 is sufficient and to investigate which
regions of PSGL-1 are necessary and/or sufficient for at-
tachment and rolling on E- and P-selectin, we developed
an in vitro assay that allowed us to study, under flow, the
interaction of various regions of extracellular PSGL-1, in iso-
lation, with cellular monolayers expressing E- or P-selectin.
The results demonstrate that PSGL-1 is sufficient to me-
diate attachment and rolling on both P- and E-selectin,
thereby extending previous studies describing PSGL-1 in-
volvement in neutrophil and HL-60 cell adhesion to E- and
P-selectin under flow (35, 38) and PSGL-1 recognition of
Figure 7. Effect of neuraminidase treatment
of 19.ek.Fc microsphere adhesive interactions
with CHO-E and -P monolayers. Micro-
spheres were coated with 50 mg/ml 19.ek.Fc,
treated with neuraminidase, and perfused
over CHO-E (open bars) or CHO-P (filled
bars) monolayers. (a) The rate of attachment
to CHO-E monolayers was significantly di-
minished, if not eliminated, by treatment with
neuraminidase. (b) In contrast, the rate of at-
tachment to CHO-P monolayers was unaf-
fected by neuraminidase treatment. (c) Accu-
mulation of 19.ek.Fc microspheres on CHO-P
monolayers was significantly diminished by
treatment with neuraminidase. (Shear stress 5
2 dynes/cm2; *P , 0.05; n 5 3).Goetz et al. PSGL-1-mediated Attachment of Microspheres 517
E- and P-selectin in biochemical assays (5, 42, 44). Micro-
spheres coated with a truncated version of extracellular
PSGL-1 fused to the Fc region of human IgG1, 148.Fc, at-
tached and rolled on TNF-a–activated HUVEC, which
have been shown to express high levels of E-selectin (7),
and on CHO-E and -P monolayers. The specificity of this
interaction was demonstrated by the following experimen-
tal results: (a) The interactions were abolished by func-
tion-blocking mAbs to E- and P-selectin but not by control
mAbs; (b) microspheres coated with human IgG1 did not
attach or roll on these substrates; (c) 148.Fc microspheres
did not interact with unstimulated HUVEC or the paren-
tal CHO cell monolayers; and (d) 148.Fc microspheres pre-
treated with OSGE, an enzyme known to cleave PSGL-1
(37), did not attach to CHO-E or -P monolayers.
The results demonstrate that as few as the first 19 amino
acids of PSGL-1 are sufficient for attachment and rolling
on both P- and E-selectin. The results also show that the
NH2-terminal anionic polypeptide segment of PSGL-1 is
necessary for PSGL-1–mediated attachment to P- but not
E-selectin. This was demonstrated by two sets of experi-
ments. First, microspheres coated with the DY.Fc mutant,
a mutated form of the 148.Fc chimera with an internal de-
letion within the anionic polypeptide sequence, specifically
amino acids 5–11 (44), did not attach to CHO-P monolayers
but attached and rolled on CHO-E monolayers. Secondly,
a neutralizing mAb to PSGL-1, KPL1, which requires the
same amino acid sequence 5–11 of PSGL-1 for recognition
(Table I), eliminated the attachment of 148.Fc microspheres
to CHO-P but not to CHO-E monolayers. Previously it
was reported that at least one sulfated tyrosine within the
NH2-terminal anionic polypeptide segment of PSGL-1 is
critical for P-selectin binding under static conditions (42,
44) and that treatment of HL-60 cells with an inhibitor of
sulfation attenuates accumulation of HL-60 cells on immo-
bilized P-selectin (42). These earlier observations, com-
bined with the present findings, suggest that at least one
sulfated tyrosine within the NH2-terminal anionic poly-
peptide segment is necessary for PSGL-1–mediated at-
tachment to P-selectin under flow.
The experimental results indicate that SLex plays a criti-
cal role in PSGL-1 amino terminus–mediated attachment
to P- and E-selectin. Neuraminidase digestion of 19.ek.Fc
microspheres, under a relatively low substrate to enzyme
ratio, essentially abolished attachment of 19.ek.Fc micro-
spheres to both CHO-P and -E monolayers. Mass and NMR
spectroscopy of the enterokinase-liberated PSGL-1 pep-
tide from 19.ek.Fc indicated that of the two potential sites
of glycosylation, only Thr-16 is glycosylated, and this gly-
can contains SLex (data not shown). These observations
combined with previous studies describing SLex as a ligand
for E- and P-selectin (15, 41, 53) strongly suggest that an
SLex-type moiety is necessary for the first 19 amino acids
of PSGL-1 to mediate attachment to P- and E-selectin and
that this moiety can be provided by the SLex-containing
glycan at Thr-16. When the neuraminidase digestion ex-
periment was repeated but with a higher substrate to en-
zyme ratio, attachment of 19.ek.Fc microspheres to CHO-E
monolayers alone was inhibited. This result suggests that
incomplete desialylation resulted in 19.ek.Fc microspheres
containing residual SLex. This level of SLex, while suffi-
cient to allow attachment of 19.ek.Fc microspheres to the
CHO-P monolayer, did not appear to allow attachment to
the CHO-E monolayer. Thus, PSGL-1 amino terminus–
mediated attachment to the CHO-E monolayer is more
sensitive to the quantity of intact SLex presented by Thr-
16 relative to the sensitivity of attachment to the CHO-P
monolayer. This difference in sensitivity may indicate that
the NH2-terminal anionic polypeptide region of PSGL-1
plays a significant role in attachment to P-selectin but
plays a lesser, if any, role in attachment to E-selectin.
These observations are consistent with previous studies
demonstrating that: (a) P-selectin has a 50-fold higher af-
finity for PSGL-1 than does E-selectin (34); (b) prolonged
digestion of PSGL-1 with neuraminidase is required to
fully eliminate recognition of P-selectin (33); and (c) one or
more of the amino-terminal tyrosines within the anionic poly-
peptide region plays an important role in PSGL-1 amino
terminus recognition of P-selectin, but plays a lesser, if any,
role in recognition of E-selectin under static conditions (44).
Subsequent to attachment, SLex appears to be critically
involved in PSGL-1 amino terminus–mediated stable roll-
ing (relatively low rolling velocities and low rates of de-
tachment) on the P-selectin monolayer. This assertion is
suggested by the neuraminidase experiment described above.
Under neuraminidase digestion conditions where it ap-
peared that residual SLex still allowed normal attachment
of 19.ek.Fc microspheres to the CHO-P monolayer, a sig-
nificant increase in rolling velocity and rate of detachment
relative to undigested 19.ek.Fc microspheres was ob-
served. Since 19.ek.Fc microspheres attach and stably roll
on CHO-P monolayers, it appears that the SLex-contain-
ing glycan at Thr-16 can provide the SLex-type moiety nec-
essary for stable rolling on P-selectin. In longer forms of
PSGL-1 that contain additional sites of glycosylation, a
glycan other than that present on Thr-16 could potentially
contribute the SLex-type moiety required to achieve stable
rolling on P-selectin.
Under flow conditions, PSGL-1 appears to have more
than one binding site for E-selectin. As noted above, mi-
crospheres coated with 19.ek.Fc, a PSGL-1 construct con-
taining a single site of glycosylation at Thr-16, attach and
roll on CHO-E monolayers. When treated with KPL1, an
mAb specific to PSGL-1, 19.ek.Fc microspheres no longer
attach to CHO-E monolayers. Interestingly, while KPL1
was shown here to require a PSGL-1 epitope located
within amino acids 5–11 for recognition, it also appears to
disrupt E-selectin recognition of the SLex glycan found at
Thr-16, perhaps via steric restrictions. However, KPL1
treatment of microspheres coated with 148.Fc, a construct
that also contains at its NH2 terminus the 19–amino acid
PSGL-1 sequence found in 19.ek.Fc, did not inhibit attach-
ment to CHO-E monolayers suggesting that sites COOH-
terminal to amino acid 19 can support attachment. The Fc
portions of the PSGL-1.Fc chimeras do not appear to me-
diate attachment to CHO-E monolayers. This is shown by
the observation that 148.Fc microspheres digested with
OSGE did not attach to CHO-E (or CHO-P) monolayers
(Fig. 5 B) and by the fact that microspheres prepared with
50 mg/ml of human Fc derived from enterokinase-digested
19.ek.Fc did not interact with CHO-E (or CHO-P) mono-
layers at all shear stresses tested ranging from 0.5 to 2.0
dynes/cm2 (data not shown). Thus, as suggested by Patel et al.
(38), PSGL-1 appears to have more than one binding siteThe Journal of Cell Biology, Volume 137, 1997 518
for E-selectin. The data presented in this study indicate
that PSGL-1 contains a binding site for E-selectin located
within the first 19 amino acids, presumably the SLex-con-
taining glycan at Thr-16, and one (or more) binding sites
located between amino acids 19 through 148, perhaps an-
other SLex-containing glycan. Both of these binding sites
appear to mediate attachment and rolling on CHO-E mono-
layers. These assertions seem plausible in light of the re-
cent findings that PSGL-1 is a highly extended molecule (26)
and PSGL-1 has several sites of potential glycosylation be-
tween amino acids 19 through 148 (44) (Fig. 6 a), many of
which may have glycans that recognize E-selectin (54).
The experimental results presented in this study, as well
as a recent report by Brunk et al. (10), give insight into se-
lectin-mediated attachment and rolling. von Andrian et al.
(51) recently reported that localization of adhesion mole-
cules on the tips of the microvilli, as opposed to the cell
body, enhances the ability of the adhesion molecules to
mediate cell attachment under flow. Thus, on neutrophils,
localization of PSGL-1 to the microvilli (35) gives PSGL-1
the opportunity to form a bond with E- or P-selectin.
Given that PSGL-1 “sees” E- or P-selectin, the following
issue arises: Will bonds form between the receptors, and
will the formed bonds mediate attachment and rolling?
Previously, Alon et al. (3) measured the off rate for the
P-selectin–neutrophil counter-receptor bond and attrib-
uted the ability of this bond to mediate rolling to its
unique kinetic and tensile properties. Mathematical mod-
els of neutrophil rolling have also indicated that unique
tensile features of the selectin bonds confer the ability of
these bonds to support rolling (14, 47). It is unclear if these
unique properties are governed primarily by the molecular
structure of the receptors or by cellular attributes and
functions. We have shown that PSGL-1 immobilized on in-
ert, nondeformable microspheres attach and roll on E- and
P-selectin–presenting monolayers. Thus, given that PSGL-1
“sees” E- or P-selectin, the molecular structure of the re-
ceptors may be the key factor in determining whether
bonds will form between the receptors and whether the
formed bonds will give rise to rolling.
Finally, the issue of whether PSGL-1 is sufficient to sup-
port adhesive interactions with P- and E-selectin has prac-
tical ramifications for potential drug delivery strategies.
With the identification and characterization of E-selectin
(7, 8), P-selectin (32), PSGL-1 (33, 43), and their synergis-
tic behavior (35, 38), the potential exists for targeting ther-
apeutic agents to sites of inflammation via adhesion mole-
cules selectively expressed on activated endothelium, e.g.,
E-selectin, and an artificial carrier, presenting PSGL-1.
The experimental results presented in this study demon-
strate that PSGL-1 is sufficient to mediate selective attach-
ment to activated endothelium under fluid flow, suggest-
ing that such delivery strategies are feasible.
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